FINWIRES · TerminalLIVE
FINWIRES

Update: Beta Bionics, Senseonics to Integrate Diabetes Devices; Shares Rise

By

(Updates with the latest stock price in the headline and last paragraph.)

Beta Bionics (BBNX) reported Tuesday a partnership to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics' (SENS) Eversense 365 continuous glucose monitoring system.

The company said it expects to launch the integrated iLet and Eversense 365 system commercially in Q4.

Beta Bionics said the integration will give iLet users access to more continuous glucose monitoring options.

The companies also plan to integrate the mint system with Eversense 365 in the future, the company added.

Shares of Beta Bionics were up over 4% in afternoon trading, while Senseonics stock was up more than 1%.

Price: $22.98, Change: $+0.94, Percent Change: +4.26%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA